Personalized Treatment Planning for Non-Small Cell Lung Cancer
(PRiMAL Trial)
Trial Summary
What is the purpose of this trial?
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
Do I need to stop my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Molecular Tumor Board Assisted Care for Non-Small Cell Lung Cancer?
Molecular tumor boards (MTBs) help doctors make better treatment decisions for patients with complex cancer cases by providing personalized recommendations based on the patient's unique genetic makeup. Studies show that MTBs improve access to targeted therapies and help avoid unnecessary treatments, which can save costs and reduce side effects.12345
How is Molecular Tumor Board Assisted Care different from other treatments for non-small cell lung cancer?
Molecular Tumor Board Assisted Care is unique because it uses a team of experts to analyze the genetic makeup of a patient's tumor and recommend personalized treatment options. This approach tailors therapy to the individual's specific tumor characteristics, potentially improving outcomes compared to standard treatments that do not consider these unique genetic factors.12567
Research Team
Timothy Mullett, MD
Principal Investigator
University of Kentucky
Eligibility Criteria
This trial is for adults with stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) who haven't had systemic therapies, except possibly adjuvant therapy for early-stage cancer. They can have had surgery or radiation and must be able to consent to treatment. It's not open to pregnant individuals or those with uncontrolled illnesses that could interfere with the trial.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Molecular Tumor Board assisted care or usual care for their NSCLC
Follow-up
Participants are monitored for overall survival and other outcomes
Treatment Details
Interventions
- Molecular Tumor Board Assisted Care
Find a Clinic Near You
Who Is Running the Clinical Trial?
Timothy Mullett
Lead Sponsor
Jill M Kolesar
Lead Sponsor
Eli Lilly and Company
Industry Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University